Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tawanda Gumbo

Showing results (191-200 of 204) with videos related to

Pageof 21
Sort By:
The Journal of Infectious Diseases|December 17, 2024
Imipenem pharmacokinetics/pharmacodynamics in preclinical hollow fiber model, dose-finding in virtual patients, and clinical evidence of efficacy for Mycobacterium abscessus lung diseaseSanjay Singh, Tawanda Gumbo, Jann-Yuan Wang, et al.
Nature Medicine|March 9, 2023
Comparison of two diagnostic intervention packages for community-based active case finding for tuberculosis: an open-label randomized controlled trialAliasgar Esmail, Philippa Randall, Suzette Oelofse, et al.
Nature Medicine|July 1, 2020
Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosisGrant Theron, Jason Limberis, Rouxjeane Venter, et al.
Frontiers in Microbiology|August 28, 2020
sncRNA-1 Is a Small Noncoding RNA Produced by <i>Mycobacterium tuberculosis</i> in Infected Cells That Positively Regulates Genes Coupled to Oleic Acid BiosynthesisFatma S Coskun, Shashikant Srivastava, Prithvi Raj, et al.
The Journal of Antimicrobial Chemotherapy|May 1, 2019
Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical modelsMike M Ruth, Gesham Magombedze, Tawanda Gumbo, et al.
American Journal of Respiratory and Critical Care Medicine|December 21, 2019
A Human Lung Challenge Model to Evaluate the Safety and Immunogenicity of PPD and Live Bacillus Calmette-GuérinMalika Davids, Anil Pooran, Clemens Hermann, et al.
The Journal of Antimicrobial Chemotherapy|June 9, 2022
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosisKamunkhwala Gausi, Maxwell Chirehwa, Elisa H Ignatius, et al.
American Journal of Respiratory and Critical Care Medicine|June 8, 2018
Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with TuberculosisKeertan Dheda, Laura Lenders, Gesham Magombedze, et al.
American Journal of Respiratory and Critical Care Medicine|January 30, 2019
Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA SequencingKeertan Dheda, Laura Lenders, Shashikant Srivastava, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2018
d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian DealDevyani Deshpande, Jan-Willem C Alffenaar, Claudio U Köser, et al.
Pageof 21

Showing results (191-200 of 204) with videos related to

Sort By:
Pageof 21
The Journal of Infectious Diseases|December 17, 2024
Imipenem pharmacokinetics/pharmacodynamics in preclinical hollow fiber model, dose-finding in virtual patients, and clinical evidence of efficacy for Mycobacterium abscessus lung diseaseSanjay Singh, Tawanda Gumbo, Jann-Yuan Wang, et al.
Nature Medicine|March 9, 2023
Comparison of two diagnostic intervention packages for community-based active case finding for tuberculosis: an open-label randomized controlled trialAliasgar Esmail, Philippa Randall, Suzette Oelofse, et al.
Nature Medicine|July 1, 2020
Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosisGrant Theron, Jason Limberis, Rouxjeane Venter, et al.
Frontiers in Microbiology|August 28, 2020
sncRNA-1 Is a Small Noncoding RNA Produced by <i>Mycobacterium tuberculosis</i> in Infected Cells That Positively Regulates Genes Coupled to Oleic Acid BiosynthesisFatma S Coskun, Shashikant Srivastava, Prithvi Raj, et al.
The Journal of Antimicrobial Chemotherapy|May 1, 2019
Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical modelsMike M Ruth, Gesham Magombedze, Tawanda Gumbo, et al.
American Journal of Respiratory and Critical Care Medicine|December 21, 2019
A Human Lung Challenge Model to Evaluate the Safety and Immunogenicity of PPD and Live Bacillus Calmette-GuérinMalika Davids, Anil Pooran, Clemens Hermann, et al.
The Journal of Antimicrobial Chemotherapy|June 9, 2022
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosisKamunkhwala Gausi, Maxwell Chirehwa, Elisa H Ignatius, et al.
American Journal of Respiratory and Critical Care Medicine|June 8, 2018
Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with TuberculosisKeertan Dheda, Laura Lenders, Gesham Magombedze, et al.
American Journal of Respiratory and Critical Care Medicine|January 30, 2019
Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA SequencingKeertan Dheda, Laura Lenders, Shashikant Srivastava, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2018
d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian DealDevyani Deshpande, Jan-Willem C Alffenaar, Claudio U Köser, et al.
Pageof 21